Julie Lorraine Rosenthal

Proud to share our review on transthyretin amyloid cardiomyopathy! doi.org/10.1007/s40119… We break down the current treatments, what’s in the pipeline, and what’s next. @UreyTony @UCSDCardiology

“Ejection Fraction: It’s Just a Fraction” youtube.com/watch?v=DrstPQ… Dr. Julie Rosenthal, Director of the Cardiac Amyloidosis Program at Mayo Clinic in Arizona, introduces us to the cardiovascular system and summarizes cardiac amyloidosis. She then discusses the echocardiogram and…

The July issue @JCardFail is out! This month we welcome our new #FunctionNotFailure trainees as well as those in all 🫀disciplines! Sharing thoughts on the #zen notion of a #BeginnersMind 👇🏽👇🏽👇🏽 whether a new trainee or well advanced in career… @robmentz…

Save the date for the the 2026 International Symposium on Amyloidosis! Join leading clinicians, researchers, and scientists from around the globe at the premier meeting dedicated to amyloidosis and protein-folding diseases. Stay tuned for more details: isaamyloidosis.org/isa-symposium/

HFA Eugene Braunwald Lecture by @WilfriedMullens - Lynne Warner Stevenson and her incredible contribution to HF Lead investigator 500+ publications Editorial board member 7 journals Contributor to 30+ HF guidelines Trained 70 HF fellows (50% women) #HeartFailure2025

Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert Consensus: @JACCJournals 🥸 @DrAROrkaby introduced me to @DrNikkiBart - and this turned out to be a great project 😱From @ACCinTouch geriatric cardiology leadership council: Summary 👇👇👇

🙏 to @RolaKhedrakiMD @RajeevCMohan @jtheywood for discussing our evolving understanding of ICI myocarditis at @ScrippsHealth—a new dz process in #cardioonc that will inevitably require all hands on deck in 🫀 given ⬆️ use in a huge % of cancer pts Great lineup & session!!

Please share this exciting and interactive Amyloid case based seminar w/your fellow Amyloid champions and trainees. @BrettSperryMD @maz_hanna @MelissaLyleMD @MarthaGrogan1 @MasriAhmadMD @YevgeniyBr @MKIttlesonMD @Ron_Witteles @Rfonsi1 @KMAlexanderMD

April is Donate Life Month. #Donate @DonateLife @MayoTransplant @UNOSNews @aqel_bashar @SamiAlasfar @Blankmd22 @brianhardaway @MathurAmitK @JonathanDCunha1 @MayoClinic @MayoAmyloid #carpediem. 🫀Honored to be a part of our patients journeys and this transplant team.

First AL #amyloidosis mouse model with cardiac dysfunction phenotype nature.com/articles/s4146…

Top3 heart failure trials in March 2025 🥇Urinary Na analysis: The 🔑to effective diuretic titration @escardio 🥈Simultaneous or rapid initiation of combination therapy for HFpEF @JAMACardio 🥉KF specific thresholds for NTproBNP in HF risk prediction among 👥 CKD @Heart_BMJ

Join Cardiologist @KSharmaMD for this one-hour, informative webinar about Living with Heart Failure. Presentation concludes with the opportunity to ask Dr. Sharma questions live. @HopkinsMedicine Register at hopkins.org/4bHAzgd

A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B trial hit 10/10 prespecified endpoints including improved all-cause mortality. Congratulations to everyone who contributed to the development/approval, and a…

And then there were 3! @Ron_Witteles @MasriAhmadMD @MarthaGrogan1 @maz_hanna @BrettSperryMD @KMAlexanderMD @YevgeniyBr @MelissaLyleMD @Rfonsi1 @JLGrodin investors.alnylam.com/press-release?…

📢 Fellowship Opportunity! Apply Now! 🏥 The Medical University of South Carolina’s Division of Cardiology is now accepting applications for a one-year, non-ACGME Amyloidosis Fellowship. 🔬 Gain specialized clinical & research training in amyloidosis and advance your expertise!

I am happy to to speak @AHAScience National AL-Amyloidosis Patient-to-Provider Connection Forum, a virtual half-day summit on March 12 1-5 PM ET. Register for the event here: heart.zoom.us/meeting/regist…

Amazing review on supportive care in #Amyloidosis by Dr. Eli Muchtar and co-authors @ISA_Amyloidosis! @vsanchorawala tinyurl.com/rz5s3u9h

We are excited to share our perspective on building a multidisciplinary Amyloidosis program from the ground up. Challenges and ways we overcame them. Thank you @ACCinTouch for the platform to share our story @TJUHospital @CU_Cardiology acc.org/Latest-in-Card…

As ❤ month closes, let's not lose sight of recent advances in TTR Amyloid - my thoughts in @JCardFail w/ @PalomaRemior on tafamidis in the real world and newer therapies entering the arena. Will the data support tafamidis' 1st mover advantage? sciencedirect.com/science/articl…